Investor Presentation

Future Growth Avenues Increased Functionality, Indications and Regions Increased functionality of existing XV LVAS product Ability to provide additional functionality to the existing XV product post deployment allows for greater ability to command a pricing premium • Ability to increase average revenue per test at little to no additional cost to the business Deployment of new products on the XV Technology platform • • • Utilise XV Technology platform to deploy new products to market, including CFPA (Vasculature) and premium combination product VQ SaaS business model allows new products to be immediately launched to existing hospitals on the XV Technology platform, enabling increased market penetration and immediate hospital take up Preparation for relevant FDA Clearances has already commenced, commercialisation of new products expected from 2021 US reimbursement • US reimbursement in the future has potential to supercharge growth Expansion of global presence . . SaaS business model allows for global scale up throughout major respiratory diagnostic markets globally FDA Clearance de-risks and/or fast-tracks approvals in other jurisdictions Utilisation of distribution agents in additional countries provides vast network of future sales opportunities via a capital light model Leverage the experience and expertise of in-house sales team to ensure optimal expansion strategy with third party distribution agents 4DMedical XVLVAS 0.24 L 55.9 2 Hospital Pg 31 | Investor presentation 4DMedical™ FORMERLY 4D

View entire presentation